REGN Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of 21.93%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Bristol-Myers Squibb's return on equity of 32.01%.

Regeneron Pharmaceuticals has a consensus price target of $727.21, signalling upside risk potential of 39.24%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.10 which suggests that it could grow by 22.31%. Given that Regeneron Pharmaceuticals has higher upside potential than Bristol-Myers Squibb, analysts believe Regeneron Pharmaceuticals is more attractive than Bristol-Myers Squibb.

Regeneron Pharmaceuticals has a beta of 0.309, which suggesting that the stock is 69.074% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.378, suggesting its less volatile than the S&P 500 by 62.23%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.34%. Bristol-Myers Squibb offers a yield of 5.23% to investors and pays a quarterly dividend of $0.62 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Regeneron Pharmaceuticals's net income of $808.7M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.30x while Bristol-Myers Squibb's PE ratio is 17.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.23x versus 1.99x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of 21.68%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Eli Lilly and's return on equity of 78.25%.

Regeneron Pharmaceuticals has a consensus price target of $727.21, signalling upside risk potential of 39.24%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 22.35%. Given that Regeneron Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Regeneron Pharmaceuticals is more attractive than Eli Lilly and.

Regeneron Pharmaceuticals has a beta of 0.309, which suggesting that the stock is 69.074% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.34%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Regeneron Pharmaceuticals's net income of $808.7M is lower than Eli Lilly and's net income of $2.8B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.30x while Eli Lilly and's PE ratio is 63.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.23x versus 14.34x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of -907.48%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Moderna's return on equity of -29.23%.

Regeneron Pharmaceuticals has a consensus price target of $727.21, signalling upside risk potential of 39.24%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 77.58%. Given that Moderna has higher upside potential than Regeneron Pharmaceuticals, analysts believe Moderna is more attractive than Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals has a beta of 0.309, which suggesting that the stock is 69.074% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.34%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are larger than Moderna quarterly revenues of $107M. Regeneron Pharmaceuticals's net income of $808.7M is higher than Moderna's net income of -$971M. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.30x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.23x versus 3.32x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 26.7% compared to Regeneron Pharmaceuticals's net margin of 21.63%. Regeneron Pharmaceuticals's return on equity of 15.7% beat Pfizer's return on equity of 8.72%.

Regeneron Pharmaceuticals has a consensus price target of $727.21, signalling upside risk potential of 39.24%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 20.27%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Regeneron Pharmaceuticals has a beta of 0.309, which suggesting that the stock is 69.074% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Regeneron Pharmaceuticals has a quarterly dividend of $0.88 per share corresponding to a yield of 0.34%. Pfizer offers a yield of 6.99% to investors and pays a quarterly dividend of $0.43 per share. Regeneron Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Regeneron Pharmaceuticals quarterly revenues are $3B, which are smaller than Pfizer quarterly revenues of $13.7B. Regeneron Pharmaceuticals's net income of $808.7M is lower than Pfizer's net income of $3B. Notably, Regeneron Pharmaceuticals's price-to-earnings ratio is 13.30x while Pfizer's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regeneron Pharmaceuticals is 4.23x versus 2.22x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.